Published: 2021-11-05

ISSUE HIGHLIGHTS

Clinical Management Recommendations

Psoriasis Therapy Beyond Biologics

Connor R Buechler, Jesse Veenstra, Linda Stein Gold
| DOI https://doi.org/10.25251/skin.5.6.1

Page 568-578

PDF KOL SUMMARY

In-Depth Reviews

Melanoma Recurrence after Mohs Micrographic Surgery with MART-1: A Systematic Review and Meta-analysis

Tyler Long, Austin Dunn, Mary Arndt, Eric Parlette
| DOI https://doi.org/10.25251/skin.5.6.2

Page 579-589

PDF

Pathophysiology, Risk Factors, and Prevention of Wound Dehiscence Following Dermatologic Procedures

Andrew Armenta, Frank Winsett, Richard Wagner
| DOI https://doi.org/10.25251/skin.5.6.3

Page 590-600

PDF

Light and Laser-based Treatments for Hidradenitis Suppurativa: A Systematic Review

Ilya Mukovozov, Sara Mirali, Sofi Khaslavsky, Sunil Kalia
| DOI https://doi.org/10.25251/skin.5.6.4

Page 601-620

PDF

Original Research

A Machine Learning-Based Test for Predicting Response to Psoriasis Biologics

Jerry Bagel, Yipeng Wang, Paul Montgomery, III, Christian Abaya, Eric Andrade, Courtney Boyce, Tatiana Tomich, Byung-In Lee, David Pariser, Alan Menter, Tobin Dickerson
| DOI https://doi.org/10.25251/skin.5.6.5

Page 621-638

PDF

Disparities in Access to Teledermatology During the COVID-19 Pandemic in Detroit, Michigan

Angela Jiang, Reem Kashlan, Christine Joseph, Amy Tang, Henry Lim
| DOI https://doi.org/10.25251/skin.5.6.6

Page 639-648

PDF

Willingness of Patients from an Urban Safety-Net Dermatology Clinic to Receive a COVID-19 Vaccine

Hannah Mumber, Daniela Del Campo, Manuel Alvarado, Jacqueline Watchmaker
| DOI https://doi.org/10.25251/skin.5.6.7

Page 649-655

PDF

Research Letters

Virtual medical student dermatologic surgery workshop increases confidence in suturing and skin biopsy skills in the era of COVID-19

Emily Dando, MD, Angela Guerrero, MD, Mary-Katharine Collins, Alaina J. James
| DOI https://doi.org/10.25251/skin.5.6.8

Page 656-659

PDF KOL SUMMARY

COVID Concepts

Pemphigus Foliaceous after COVID-19 Infection and Bamlanivimab Infusion

Katelyn Urban, Rachel L. Giesey, Gregory R. Delost
| DOI https://doi.org/10.25251/skin.5.6.9

Page 660-663

PDF

Brief Articles

Rare Mucosal Lip Atypical Fibroxanthoma Treated with Mohs Micrographic Surgery

Tara Howard, Taraneh Matin, John Howard, Eduardo Weiss Howard
| DOI https://doi.org/10.25251/skin.5.6.10

Page 664-666

PDF

Rapid Efficacy of Ixekizumab for Pediatric Acute Generalized Pustular Psoriasis

Linda Serrano, Valerie Carlberg, Kristen Holland
| DOI https://doi.org/10.25251/skin.5.6.11

Page 667-671

PDF

Diffuse Large B-cell Lymphoma in Bilateral Lower Extremities

Leon Kou, Kevyn Niu, Austin Wong, Aaron Chen, Sid Danesh
| DOI https://doi.org/10.25251/skin.5.6.12

Page 672-675

PDF

Atypical Targetoid Lesions as the Presenting Sign of Myeloid Sarcoma

Eduardo Adrian Rodriguez, Edward Visnaw, Frank Petr, Huma Siddiqui
| DOI https://doi.org/10.25251/skin.5.6.13

Page 676-679

PDF

A Cross-Sectional Survey of Students and Instructors on Virtual Dermatology Teaching in a Competency-based Format

Shara Chopra, Ankita Sinharoy, Alexandra Flamm
| DOI https://doi.org/10.25251/skin.5.6.14

Page 680-684

PDF

Multinucleate Cell Angiohistiocytoma: A Case Report and Unique Treatment Consideration

Maria Karim , Marlyn Wu, Adriana Ros
| DOI https://doi.org/10.25251/skin.5.6.15

Page 685-688

PDF

Dermatofibrosarcoma Protuberans Presenting as a Subcutaneous Cystic Nodule

Chris Logas, Austin Dunn, Danielle Lazarra, Justin Rubin, Eli Saleeby, Brad Glick
| DOI https://doi.org/10.25251/skin.5.6.16

Page 689-692

PDF

Successful Use of Apremilast in Psoriasiform Dermatitis Refractory to Biologics

Christopher Yang, Victor Quan, Ahmad Amin
| DOI https://doi.org/10.25251/skin.5.6.17

Page 693-696

PDF

Primary Cutaneous Plasmacytoma Treated with Palliative Radiotherapy: A Case Report and Literature Review

Suzanne Alkul, Yuangao Liu , Scott Whipple, Gordana Verstovsek, Soo Jung Kim
| DOI https://doi.org/10.25251/skin.5.6.18

Page 697-701

PDF

Short Communications

A Thousand Words for a Picture of Health

Amy Blake
| DOI https://doi.org/10.25251/skin.5.6.19

Page 702-703

PDF

Compelling Comments

Social Media and Skin Cancer Prevention: A Promising Platform for Education Among Adolescents and Young Adults

Mary Cavanagh, Brinda Chellappan
| DOI https://doi.org/10.25251/skin.5.6.20

Page 704-705

PDF

Poster Presentations from FC21 Dermatology Conference®: Psoriasis

A Phase 3, Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Parallel Group Trial Investigating the Efficacy and Safety of Clobetasol Propionate Cream, 0.025% in the Treatment of Moderate to Severe Plaque Psoriasis for 14 Days

Seemal Desai, Zoe Draelos, Steve Feldman, J. Mark Jackson
| DOI https://doi.org/10.25251/skin.5.supp.33

Page s33

Poster PDF

Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Efficacy by Baseline Disease Characteristics and Demographics in Two Pivotal Phase 3 Trials

Leon Kircik, Linda Stein Gold, James Del Rosso, Seemal Desai, Brad Glick, Howard Sofen, Anna Tallman, David Rubenstein, Philip Brown
| DOI https://doi.org/10.25251/skin.5.supp.34

Page s34

Poster PDF

Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Long-Term Extension Trial of a Novel Therapeutic Aryl Hydrocarbon Receptor Modulating Agent

Bruce Strober , Linda Stein Gold, Robert Bissonnette, April Armstrong , Andrew Blauvelt, Philip Brown, Leon Kircik, Anna Tallman, Mark Lebwohl
| DOI https://doi.org/10.25251/skin.5.supp.35

Page s35

Poster PDF

Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Versus Placebo and Apremilast in Moderate to Severe Plaque Psoriasis: Efficacy Analysis by Baseline Disease Characteristics From the Phase 3 POETYK PSO-1 and PSO-2 Trials

Joe Merola, Howard Sofen, Diamant Thaci, Carle Paul, Shinichi Imafuku, Subhashis Banerjee, April Armstrong
| DOI https://doi.org/10.25251/skin.5.supp.36

Page s36

Poster PDF

Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Compared With Placebo and Apremilast in Moderate to Severe Psoriasis: Integrated Laboratory Parameter Results From the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials

Diamant Thaci, Kenneth Gordon , Melinda Gooderham, Bruce Strober , Neil Korman, Subhashis Banerjee, Subhashis Banerjee, Elizabeth Colston, Jonghyeon Kim, John Throup, Akimichi Morita
| DOI https://doi.org/10.25251/skin.5.supp.37

Page s37

Poster PDF

Deucravacitinib Improves Psoriasis Symptoms and Signs Diary Domain Scores in Patients With Moderate to Severe Plaque Psoriasis: Results From the Phase 3 POETYK PSO-1 and POETYK PSO-2 Studies

April Armstrong , Bruce Strober , Kenneth Gordon , Joe Zhuo, Brandon Becker, Renata Kisa, John Throup, Jonghyeon Kim, Kim Papp
| DOI https://doi.org/10.25251/skin.5.supp.38

Page s38

Poster PDF

Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Versus Placebo and Apremilast in Moderate to Severe Plaque Psoriasis: Onset of Action in the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials

Neil Korman, Kim Papp, Jerry Bagel, Peter Foley, Akimichi Morita, Subhashis Banerjee, Elizabeth Colston, Tao Wang, John Throup, Diamant Thaci
| DOI https://doi.org/10.25251/skin.5.supp.39

Page s39

Poster PDF

A randomized, investigator-blinded study to compare the efficacy and tolerance of a 650-microsecond, 1064-nm YAG laser to a 308-nm excimer laser for the treatment of mild-to-moderate psoriasis vulgaris

Mark Nestor, Daniel Fischer, David Arnold, Haowei Han, Anita Gade, Francesca Ceci, Austin Dunn, Alec Lawson
| DOI https://doi.org/10.25251/skin.5.supp.40

Page s40

Poster PDF

Roflumilast Cream 0.3% Improved the Severity and Impact of Itch in Patients With Chronic Plaque Psoriasis in the Phase 3 DERMIS-1 and DERMIS-2 Studies

Javier Alonso-Llamazares, Melinda Gooderham, Jerry Bagel, John Browning, Zoe Draelos, Kimberly Grande, Adelaide Herbert, Wei Jing Loo, Chih-ho Hong, Mark Lebwohl, Walter Nahm, Kim Papp, David Pariser, Jennifer Soung, Linda Stein Gold, Irina Turchin, Amy Feng, Patrick Burnett, Robert Higham, David Berk
| DOI https://doi.org/10.25251/skin.5.supp.41

Page s41

Poster PDF

Once-Daily Roflumilast Cream 0.3%, a Potent Phosphodiesterase-4 Inhibitor, Provided Safe and Effective Treatment of Psoriasis in the DERMIS-1 and DERMIS-2 Phase 3 Trials

Mark Lebwohl, Leon Kircik, Angela Moore, Linda Stein Gold, James Del Rosso, Zoe Draelos, Melinda Gooderham, Lawrence Green, Adelaide Herbert, Kim Papp, Jerry Bagel, Neal Bhatia, Laura Ferris, Terry Jones, Steve Kempers, David Pariser, Paul Yamauchi, Matthew Zirwas, Amy Feng, Patrick Burnett, Robert Higham, David Berk
| DOI https://doi.org/10.25251/skin.5.supp.42

Page s42

Poster PDF

Once-Daily Roflumilast Foam 0.3% Improves Severity and Burden of Itch in Patients With Scalp and Body Psoriasis in a Randomized, Double-blind, Vehicle-Controlled Phase 2b Study

Angela Moore, Javier Alonso-Llamazares, Neal Bhatia, Alim Devani, Michael Bukhalo, Zoe Draelos, Melinda Gooderham, Steve Kempers, Leon Kircik, Kim Papp, David Pariser, Marina Sankeva, Rodney Sinclair, Matthew Zirwas, Amy Feng, Patrick Burnett, Robert Higham, David Berk
| DOI https://doi.org/10.25251/skin.5.supp.43

Page s43

Poster PDF

Long-term Safety and Efficacy of Roflumilast Cream 0.3% in Adult Patients With Chronic Plaque Psoriasis: Results From a 52-Week, Phase 2b Open-Label Study

Linda Stein Gold, Melinda Gooderham, Kim Papp, Laura Ferris, Mark Lebwohl, David Adam, Javier Alonso-Llamazares, Chih-ho Hong, Steve Kempers, Leon Kircik, Wei Jing Loo, Daniel Stewart, Walter Nahm, Matthew Zirwas, Patrick Burnett, Robert Higham, Lynn Navale, David Berk
| DOI https://doi.org/10.25251/skin.5.supp.44

Page s44

Poster PDF

A Dermal Biomarker Patch Displays Excellent Analytical Performance and Outperforms Tape Stripping in Psoriatic Skin

Tobin Dickerson, Stephen Boyd, Eric Andrade, Christian Abaya, Yipeng Wang, Byung-In Lee
| DOI https://doi.org/10.25251/skin.5.supp.45

Page s45

Poster PDF

Mind.Px – Personalized Medicine for Psoriasis Biologic Treatment

Tobin Dickerson, Byung-In Lee, Paul Montgomery, Stephen Boyd, Eric Andrade, Courtney Boyce, Tatiana Tomich, Yipeng Wang
| DOI https://doi.org/10.25251/skin.5.supp.46

Page s46

Poster PDF

Phase IV Evaluation of the Adrenal Suppression Potential and PKPD of Halobetasol Propionate Foam, 0.05% in Adolescent Subjects with Plaque Psoriasis

Adelaide Herbert, Rhonda Schreiber, Debbie Glaab, Lawrence Eichenfeld
| DOI https://doi.org/10.25251/skin.5.supp.47

Page s47

Poster PDF

Long-term Safety and Efficacy of Fixed-Combination Halobetasol Propionate and Tazarotene Lotion in Patients With Clinically Meaningful Improvement in Plaque Psoriasis

Andrew Alexis, James Del Rosso, Tina Bhutani, Kim Papp, Abby Jacobson
| DOI https://doi.org/10.25251/skin.5.supp.48

Page s48

Poster PDF

Long-term Outcomes of Fixed-Combination Halobetasol Propionate and Tazarotene Lotion Stratified by Baseline Signs and Symptoms of Psoriasis

Leon Kircik, Lawrence Green, Joshua Zeichner, Javier Alonso-Llamazares, Abby Jacobson
| DOI https://doi.org/10.25251/skin.5.supp.49

Page s49

Poster PDF

Retreatment With Brodalumab Results in Skin Clearance and Improvements in Quality of Life in Patients With Psoriasis After Treatment Interruption

April Armstrong , Brian Keegan, George Han, Abby Jacobson
| DOI https://doi.org/10.25251/skin.5.supp.50

Page s50

Poster PDF

Efficacy of Brodalumab vs Ustekinumab by Prior TNFα Inhibitor Exposure: Post hoc Analysis of Two Phase 3 Psoriasis Studies

Alan Menter, Erin Boh, George Lewitt, Abby Jacobson
| DOI https://doi.org/10.25251/skin.5.supp.51

Page s51

Poster PDF

Bimekizumab response maintenance through two years of treatment in patients with moderate to severe plaque psoriasis who responded after 16 weeks: Interim results from the BE BRIGHT open-label extension trial

Bruce Strober , Akihiko Asahina, Ulrich Mrowietz, Mark Lebwohl, Peter Foley, Richard Langley, Jonathan Barker, Christopher Cioffi, Nancy Cross, Maggie Wang, Carle Paul
| DOI https://doi.org/10.25251/skin.5.supp.52

Page s52

Poster PDF

Bimekizumab versus secukinumab efficacy across subgroups of patients with moderate to severe plaque psoriasis: Results from the multicenter, randomized, double-blinded phase 3b BE RADIANT trial

Andrew Blauvelt, Lars Iversen, Sandy McBride, Melinda Gooderham, Petra Staubach, Paul Yamauchi, Fabienne Staelens, Veerle Vanoorden, Katy White, Paolo Gisondi
| DOI https://doi.org/10.25251/skin.5.supp.53

Page s53

Poster PDF

Number Needed to Treat Among Therapies for Patients with Moderate to Severe Plaque Psoriasis: Clinical Perspective of Results from a Network Meta-Analysis

C Leonardi, K Fahrbach, B Neupane, A Armstrong , K Gordon, S Kiri, V Taieb, L McClung
| DOI https://doi.org/10.25251/skin.5.supp.54

Page s54

Poster PDF

Mean percent PASI improvement with bimekizumab in patients with moderate to severe plaque psoriasis: Pooled results from four phase 3/3b trials

Andrew Blauvelt, George Han, Steve Tyring, Jennifer Soung, Tae Oh, Leah Davis, Veerle Vanoorden, Mark Lebwohl
| DOI https://doi.org/10.25251/skin.5.supp.55

Page s55

Poster PDF

Atopic Dermatitis

Neutralizing interleukin-13 increases skin microbial diversity: results from a Phase 3, randomized, double-blind, placebo-controlled trial of tralokinumab in adult patients with atopic dermatitis

Thomas Bieber, Lisa Beck, Andrew Pink, Hidehisa Saeki, Lawrence Eichenfeld, Thomas Werfel, Anders Rosholm, Mads Ropke, Amy Paller
| DOI https://doi.org/10.25251/skin.5.supp.56

Page s56

Poster PDF

Assessing long-term maintenance of efficacy with tralokinumab monotherapy in patients with moderate-to-severe atopic dermatitis: combined results from two phase 3, randomized, double-blind, placebo-controlled trials (ECZTRA 1 and 2)

Andrew Blauvelt, Anderas Wollenberg, Andrew Pink, Ketty Peris, April Armstrong , Lynda Spelman, Hidehisa Saeki, Charles Lynde, Pedro Herranz, Sebastien Barbarot, Eric Simpson
| DOI https://doi.org/10.25251/skin.5.supp.57

Page s57

Poster PDF

COVID-19 in tralokinumab-treated patients with moderate-to- severe atopic dermatitis: case series from the ECZTEND long- term extension trial

Andrew Blauvelt, Andrew Pink, Margitta Worm, Richard Langley, Antonio Costanzo, Le Gjerum, Emilie Jorgensen, Joshua Corriveau, Emma Guttman-Yassky
| DOI https://doi.org/10.25251/skin.5.supp.58

Page s58

Poster PDF

Long-Term Improvements Observed in Tralokinumab-Treated Patients with Moderate-to-Severe Atopic Dermatitis: an ECZTEND Interim Analysis

Andrew Blauvelt, Jean-Philippe Lacour, Darryl Toth, Vivian Laquer, Stefan Beissert, Andreas Wollenberg, Pedro Herranz, Andrew Pink, Ketty Peris, Stine Fangel, Hidehisa Saeki
| DOI https://doi.org/10.25251/skin.5.supp.59

Page s59

Poster PDF

Efficacy and safety of tralokinumab plus topical corticosteroids in patients with severe atopic dermatitis and prior history of dupilumab treatment: a post hoc subgroup analysis from ECZTRA 7 trial

Jan Gutermuth, Andrew Pink, Margitta Worm, Lise Soldbro, Thomas Mark, Joshua Corriveau, Christian Bjeeregard Oland, Stephan Weidinger
| DOI https://doi.org/10.25251/skin.5.supp.60

Page s60

Poster PDF

Rapid and sustained improvements in itch and sleep with tralokinumab treatment in patients with moderate-to-severe Atopic Dermatitis, a post hoc analysis of pooled data from ECZTRA 1 and 2

Eric Simpson, Anderas Wollenberg, Weily Soong, Thomas Mark, Alexandra Kuznetsova, Louise Abildgaard Steffensen, Jonathan Silverberg
| DOI https://doi.org/10.25251/skin.5.supp.61

Page s61

Poster PDF

Tapinarof Cream 1% Once Daily for the Treatment of Moderate to Severe Atopic Dermatitis in Children and Adults: The Pivotal Phase 3 ADORING Clinical Program

Lawrence Eichenfeld, Jonathan Silverberg, Robert Bissonnette, Anna Tallman, David Rubenstein, Stephen Piscitelli, John Jett
| DOI https://doi.org/10.25251/skin.5.supp.62

Page s62

Poster PDF

Long-Term Safety and Disease Control With Ruxolitinib Cream in Atopic Dermatitis: Results From Two Phase 3 Studies

Kim Papp, Jacek Szepietowski, Leon Kircik, Darryl Toth, Lawrence Eichenfeld, Seth Forman, Michael Kuligowski, May Venturanza, Kang Sun, Eric Simpson
| DOI https://doi.org/10.25251/skin.5.supp.63

Page s63

Poster PDF

Itch-Free State in Patients With Atopic Dermatitis Treated With Ruxolitinib Cream

Andrew Blauvelt, Jacek Szepietowski, Kim Papp, Eric Simpson, Jonathan Silverberg, Brian Kim, Shawn Kwatra, Michael Kuligowski, May Venturanza, Kang Sun, Leon Kircik
| DOI https://doi.org/10.25251/skin.5.supp.64

Page s64

Poster PDF

Long-term safety and disease control with ruxolitinib cream among patients with atopic dermatitis based on previous medication history: Pooled results from two phase 3 studies

Andrew Blauvelt, Lawrence Eichenfeld, Michael Kuligowski, May Venturanza, Kang Sun, Jonathan Silverberg
| DOI https://doi.org/10.25251/skin.5.supp.65

Page s65

Poster PDF

Long-Term Safety and Disease Control With Ruxolitinib Cream in Patients With More Severe Atopic Dermatitis: Pooled Results From Two Phase 3 Studies

Eric Simpson, Leon Kircik, Andrew Blauvelt, Michael Kuligowski, May Venturanza, Kang Sun, Lawrence Eichenfeld
| DOI https://doi.org/10.25251/skin.5.supp.66

Page s66

Poster PDF

Effects of Ruxolitinib Cream in Patients With Atopic Dermatitis With Head and/or Neck Involvement

Eric Simpson, Robert Bissonnette, Michael Kuligowski, May Venturanza, Kang Sun, Jonathan Silverberg
| DOI https://doi.org/10.25251/skin.5.supp.67

Page s67

Poster PDF

Acne & Rosacea

A Clinical Evaluation of the 1064nm Nd:YAG Laser with a 650-microsecond Pulse Duration for the Treatment of Acne Vulgaris

Tanya Greywal, Nazanin Saedi, Arisa Ortiz
| DOI https://doi.org/10.25251/skin.5.supp.68

Page s68

Poster PDF

Tazarotene 0.045% Lotion for Acne: Formulation, Application Characteristics, and Clinical Efficacy and Safety

Zoe Draelos, Emil Tanghetti, Linda Stein Gold, Hilary Baldwin, Leon Kircik, Eric Guenin
| DOI https://doi.org/10.25251/skin.5.supp.69

Page s69

Poster PDF

Efficacy and Safety of Tazarotene 0.045% Lotion in White Adults with Moderate-to-Severe Acne

James Del Rosso, Linda Stein Gold, Stephen Tyring, William Philip Werschler, Fran Cook-Bolden, George Han, Neal Bhatia, Eric Guenin
| DOI https://doi.org/10.25251/skin.5.supp.70

Page s70

Poster PDF

Improvements in Acne and Skin Oiliness with Tazarotene 0.045% Lotion in Acne Patients with Oily Skin

Emil Tanghetti, Michael Gold, Neil Sadick, Fran Cook-Bolden, Leon Kircik, Linda Stein Gold, Stephen Tyring, James Del Rosso, Eric Guenin
| DOI https://doi.org/10.25251/skin.5.supp.71

Page s71

Poster PDF

Oral Sarecycline for Treatment of Papulopustular Rosacea: Results of a Pilot Study Evaluating Efficacy and Safety

James Del Rosso, Leon Kircik, Cheryl Effron, Zoe Draelos
| DOI https://doi.org/10.25251/skin.5.supp.72

Page s72

Poster PDF

Sarecycline: Rapid Improvement of Truncal Acne in Hispanic Male

Angela Moore, Stephen Moore, Luke Moore, Stephen Tyring, Stephen Tyring
| DOI https://doi.org/10.25251/skin.5.supp.73

Page s73

Poster PDF

Hyperhidrosis

Investigating Treatment of Primary Axillary Hyperhidrosis With a Topical Retrometabolic Anticholinergic Drug

Nicholas Bodor, Adam Friedman, Stacy Smith, James Del Rosso, Janet Dubois, Adelaide Herbert, Tory Sullivan, Zakiya Rice, Joe Gorlick, Leon Kircik, Lawrence Green, Brandon Kirsch, Deepak Chadha
| DOI https://doi.org/10.25251/skin.5.supp.74

Page s74

Poster PDF

Pruritus & Prurigo Nodularis

Long-term Safety and Efficacy of Difelikefalin in Subjects With Chronic Kidney Disease–Associated Pruritus: Analysis From KALM-1 and KALM-2

Steve Fishbane, Warren Wen, Catherine Munera, Frédérique Menzaghi, Kieran McCafferty
| DOI https://doi.org/10.25251/skin.5.supp.75

Page s75

Poster PDF

Oral Difelikefalin Reduces Pruritus in Atopic Dermatitis

Brian Kim, Masato Tamari, Lydia Zamidar, Kristine Nograles, Catherine Munera, Joana Goncalves, Emma Guttman-Yassky, Mark Lebwohl
| DOI https://doi.org/10.25251/skin.5.supp.76

Page s76

Poster PDF

Efficacy of Difelikefalin in Subjects With Moderate-to-Severe Chronic Kidney Disease–Associated Pruritus: Pooled Subgroup Analysis of KALM-1 and KALM-2

Joel Topf, Warren Wen, Catherine Munera, Frédérique Menzaghi, Michael Schömig
| DOI https://doi.org/10.25251/skin.5.supp.77

Page s77

Poster PDF

Skin Cancer

The Cataylst Initiative: Innovative CME on Appropriate Use of Immunotherapy in the Systemic Treatment of Locally Advanced and Metastatic BCC and cSCC

Med Learning Group
| DOI https://doi.org/10.25251/skin.5.supp.78

Page s78

Poster PDF

A comprehensive diagnostic offering workflow increases the rate of actionable results of the 23- and 35-gene expression profile tests for use as ancillary diagnostic tools for difficult-to-diagnose melanocytic lesions

Matthew Goldberg, Jennifer Siegel, Brooke Russell, Jason Rogers, Kyle Covington, Kristen Oelschlanger, Trisha Poteet, Jeffrey Wilkinson , Michael Berg, Katherine Falkowski, Sarah Kurley, Armineh Kajoian
| DOI https://doi.org/10.25251/skin.5.supp.79

Page s79

Poster PDF

Integrating the 31-gene expression profile and clinicopathologic data to determine the risk of sentinel lymph node positivity and recurrence-free survival in cutaneous melanoma

Brian Martin, Nicholas Taylor, Eric Whitman, Ann Quick, Christine Bailey, Kyle Covington, John Vetto
| DOI https://doi.org/10.25251/skin.5.supp.80

Page s80

Poster PDF

Field Treatments for Actinic Keratosis: A Systematic Review and Network Meta-Analysis

G Martin, B Berman, S Feldman, A Armstrong , M Edwards, S Graziadio, R McCool, M Arber, E Carr, D James, M Chapman-Rounds, E Fumero, M Schuchardt, A Grada
| DOI https://doi.org/10.25251/skin.5.supp.81

Page s81

Poster PDF

Determination of the Area of Skin Capable of Being Covered by the Application of 250 mg of Tirbanibulin Ointment, 1%

Austin Dunn, Haowei Han, Anita Gade, Brian Berman
| DOI https://doi.org/10.25251/skin.5.supp.82

Page s82

Poster PDF

Dermatopharmacology

Sarecycline exhibits decreased activity Against Representative Bacterial and Fungal Microflora Commonly Present in the Human Gastrointestinal Tract

Mahmoud Ghannoum, Janet Herrada, Ahmed Gamal, Lisa Long, Thomas McCormick, Ayman Grada
| DOI https://doi.org/10.25251/skin.5.supp.83

Page s83

Poster PDF

Enhanced Uptake of 2% Salicylic Acid Following 1440-nm Non-ablative Fractional Diode Laser Treatment

Jordan Wang, Paul Friedman, Adarsh Konda, Catherine Parker, Roy Geronemus
| DOI https://doi.org/10.25251/skin.5.supp.84

Page s84

Poster PDF

Enhanced Uptake of 10% Ascorbic Acid After 1440-nm or 1927-nm Non-ablative Fractional Diode Laser Treatment

Jordan Wang, Paul Friedman, Adarsh Konda, Catherine Parker, Roy Geronemus
| DOI https://doi.org/10.25251/skin.5.supp.85

Page S85

Poster PDF

Quantifying Uptake of Topical 4% Hydroquinone After 1440-nm and 1927-nm Non-ablative Fractional Diode Laser Treatment

Jordan Wang, Paul Friedman, Adarsh Konda, Catherine Parker, Roy Geronemus
| DOI https://doi.org/10.25251/skin.5.supp.86

Page s86

Poster PDF

Quantifying Uptake of Eye Serum After 1440-nm or 1927-nm Non-ablative Fractional Diode Laser Treatment

Jordan Wang, Paul Friedman, Adarsh Konda, Catherine Parker, Roy Geronemus
| DOI https://doi.org/10.25251/skin.5.supp.87

Page s87

Poster PDF

Disorders of Pigmentation

Cysteamine: Clinical efficacy, safety and tolerability versus best-in-class treatments for melasma

Seemal Desai
| DOI https://doi.org/10.25251/skin.5.supp.88

Page s88

Poster PDF

Stabilized Cysteamine 5% Cream for the Treatment of Senile Lentigo

Nasrin Saki
| DOI https://doi.org/10.25251/skin.5.supp.89

Page s89

Poster PDF

Miscellaneous

Long-Term Efficacy of a Nutraceutical Supplement for Promoting Hair Growth in Perimenopausal, Menopausal and Postmenopausal Women with Self-Perceived Thinning Hair

Glynis Ablon, Sheryl Berkowitz, Sophia Kogan, Isabelle Raymond
| DOI https://doi.org/10.25251/skin.5.supp.90

Page s90

Poster PDF

Pooled Results of VP-102 Safety and Efficacy in Phase 3 Trials for Molluscum Contagiosum by Fitzpatrick Skin Type (FST)

Elaine Siegfried, Lawrence Eichenfeld, Pearl Kwong, Seemal Desai, Susan Cutler, Cynthia Wilson, Pamela Rumney, Christine Crosby, Jennifer Andres, Mark McBride
| DOI https://doi.org/10.25251/skin.5.supp.91

Page s91

Poster PDF

Proportion of Subjects Achieving a Molluscum Lesion Count of 0 or 1 at the Day 84 End of Study Visit in Phase 3 Clinical Trials with VP-102 CAMP-1 and CAMP-2

Lawrence Eichenfeld, Elaine Siegfried, Pearl Kwong, Susan Cutler, Cynthia Willson, Pamela Rumney, Christine Crosby, Jennifer Andres, Mark McBride
| DOI https://doi.org/10.25251/skin.5.supp.92

Page s92

Poster PDF

Therapeutic Recommendations for the Treatment of Toenail Onychomycosis in the US

Shari Lipner, Warren Josepth, Tracy Vlahovic, Richard Scher, Phoebe Rich, Mahmoud Ghannoum, Ralph Daniel, Boni Elewski
| DOI https://doi.org/10.25251/skin.5.supp.93

Page s93

Poster PDF

A Randomized, Double-blind, Vehicle-Controlled Phase 2a Study Evaluating Once Daily Roflumilast Foam 0.3% in Patients With Moderate to Severe Seborrheic Dermatitis

Matthew Zirwas, Zoe Draelos, Janet Dubois, Leon Kircik, Angela Moore, Linda Stein Gold, Javier Alonso-Llamazares, Michael Bukhalo, Suzanne Bruce, Kimmie Eads, Lawrence Green, Scott Guenthner, Laura Ferris, Seth Forman, Steven Kempers, Edward Lain, Charles Lynde, David Pariser, David Pariser, Darryl Toth, paul Yamauchi, Patrick Burnett, David Berk
| DOI https://doi.org/10.25251/skin.5.supp.94

Page s94

Poster PDF